Oncology

This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.

Data from a phase 1/2 trial revealed that CRISPR–Cas9–edited donor stem cell transplants lacking CD33 enabled rapid engraftment and allowed posttransplant gemtuzumab ozogamicin maintenance in high-risk patients with AML/MDS without prolonged hematologic toxicity.

A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.

FDA approval brings the first all-oral AML combination therapy, decitabine/cedazuridine with venetoclax, for older or unfit patients, cutting clinic visits.

Phase 1b data show zongertinib delivers durable first-line responses in HER2-mutant NSCLC, including brain metastases, with manageable safety.

FDA approves sonrotoclax for patients who have received at least 2 lines of systemic therapy, including a Bruton tyrosine kinase inhibitor.

A new JAMA study links GLP-1s like Wegovy, Ozempic, Zepbound, and Mounjaro to better breast cancer survival, lower recurrence, and weight loss benefits.

Makary's 13-month tenure ends after clashes with the Trump administration over flavored vape approvals, mifepristone policy, and broader agency management.

A study finds that nearly half of older adults with mNSCLC do not receive treatment despite major advances in immunotherapy and targeted therapies that can improve survival and quality of life.

Phase 3 findings from the VIKTORIA-1 trial demonstrated clinically meaningful progression-free survival improvements with gedatolisib-based regimens in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Treatment with zenocutuzumab-zbco led to an overall response rate of 36.8% for a duration ranging from 2.8 to 12.9 months.

Forrest N. Ridgway, PharmD, BCOP, discusses health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies patients are bringing into the clinic.

Effective real-world management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) is critical to safely delivering CAR T-cell therapies and bispecific antibodies.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

Expanding education, safety responsibilities, and patient support roles are elevating the importance of pharmacy technicians in cancer care.

ENVISION trial shows mitomycin intravesical solution after TURBT delivers durable control in recurrent NMIBC, with 72% event-free at 24 months.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

Ambulatory pharmacists can address mental health gaps, tackle stigma and SDOH, and power collaborative care, improving adherence and patient quality of life.

During Hepatitis Awareness Month, learn why hepatitis B vaccination and one-time screening help prevent silent infection and cut liver cancer risk.

Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.

Jordan Hill, PharmD, BCOP, talks about the impact of the updated NCCN guidelines for triple negative breast cancer.

New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.

Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.

Phase 3 MagnetisMM-5 trial data demonstrated that Elrexfio (elranatamab) significantly improved progression-free survival compared with standard-of-care therapy in patients with relapsed or refractory multiple myeloma.

Data from COA highlight operationalizing novel therapies in community cancer care.